NCT05205746View on ClinicalTrials.gov

Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence

PHASE2CompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

November 23, 2021

Primary Completion Date

August 9, 2022

Study Completion Date

July 24, 2023

Conditions
SARS CoV 2 Infection
Interventions
BIOLOGICAL

Recombinant NDV Vectored Vaccine for SARS-CoV-2

Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2

BIOLOGICAL

Placebo

Physiological saline solution of Sodium Chloride at 0.9% After mask opening ChAdOx-1-S\[recombinant\]) Intramuscular

Trial Locations (4)

68000

Oaxaca Site Management Organization S.C., Oaxaca City

06100

Centro Mexicano de Estudios Clínicos CEMDEC SA de CV, Mexico City

06760

CAIMED Investigación en Salud S.A. de C.V., Mexico City

07760

Unidad Médico Familiar No. 20 Instituto Mexicano del Seguro Social, Mexico City

All Listed Sponsors
collaborator

National Council of Science and Technology, Mexico

OTHER

collaborator

Instituto Nacional de Enfermedades Respiratorias

OTHER_GOV

lead

Laboratorio Avi-Mex, S.A. de C.V.

INDUSTRY

NCT05205746 - Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence | Biotech Hunter | Biotech Hunter